FIG. 1 SEQ ID NO:1

SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI 50

PDGKRIIWDS RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT 100

IIDVVLSPSH GIELSVGEKL VLNCTARTEL NVGIDFNWEY PSSKHQHKKL 150

VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ GLYTCAASSG LMTKKNSTFV 200

RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD 250

VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN 300

GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL 350

TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS 400

RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G

FIG. 2



Symbol=Censor
Placebo/Folfiri
Aflibercept/Folfiri
Kaplan-Meier Estimate
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
log-rank p = 0.0032
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time (Months)
Number at Risk
Placebo 614 573 485 401 286 193 131 87 51
AFLI 612 566 498 416 311 216 148 104 75

FIG. 3



Strata (as per IVRS)
N=
HR [95.34% CI]
Favors Aflibercept
Favors Placebo
All patients
1226
0.817 (0.713 to 0.937)
ECOG PS=0
699
0.768 (0.635 to 0.928)
ECOG PS=1
500
0.869 (0.71 to 1.063)
ECOG PS=2
27
0.978 (0.43 to 2.221)
No prior bevacizumab
853
0.788 (0.669 to 0.927)
Prior bevacizumab
373
0.862 (0.673 to 1.104)
0
1
2
3
Hazard Ratio

FIG. 4

Subgroups	N=	HR [95.34% CI]
All patients	1226	0.817 (0.713 to 0.937)
Age <65	783	0.796 (0.67 to 0.945)
Age >=65	443	0.853 (0.682 to 1.066)
Male	718	0.83 (0.696 to 0.989)
Female	508	0.776 (0.625 to 0.963)
Caucasian/White	1071	0.8 (0.691 to 0.925)
Other	155	0.831 (0.561 to 1.23)
Western Europe	425	0.891 (0.712 to 1.114)
Eastern Europe	297	0.697 (0.519 to 0.934)
North America	138	0.691 (0.442 to 1.079)
South America	118	0.838 (0.53 to 1.324)
Other countries	248	0.891 (0.67 to 1.186)




FIG. 5

Subgroups	N=	HR [95.34% CI]
All patients	1226	0.817 (0.713 to 0.937)
No prior hypertension	692	0.883 (0.74 to 1.054)
Prior hypertension	534	0.714 (0.577 to 0.884)
Number of organs with metastasis <=1	535	0.767 (0.618 to 0.953)
Number of organs with metastasis >1	691	0.825 (0.692 to 0.982)
No liver metastasis, or liver and other metastases	927	0.868 (0.742 to 1.015)
Liver metastasis only	299	0.649 (0.492 to 0.855)
Colon	591	0.739 (0.607 to 0.899)
Recto sigmoid/Other	264	1.039 (0.772 to 1.4)
Rectum	371	0.806 (0.629 to 1.031)





FIG. 6


Strata (as per IVRS)
N=
HR [99.99% CI]
Favors Aflibercept
Favors Placebo
All patients
1226
0.758 (0.578 to 0.995)
ECOG PS=0
699
0.761 (0.529 to 1.094)
ECOG PS=1
500
0.749 (0.494 to 1.135)
ECOG PS=2
27
0.618 (0.11 to 3.476)
No prior bevacizumab
853
0.797 (0.58 to 1.096)
Prior bevacizumab
373
0.661 (0.399 to 1.095)
0
1
2
3
4
Hazard Ratio